Aimovig
Payments companies reported to CMS as associated with Aimovig. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Aimovig, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Aimovig
These are the largest totals companies reported as associated with Aimovig. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Stewart Tepper | Stamford, CT | Neurology (Psychiatry & Neurology) | $13,923.88 |
| Charles Hennekens | Boca Raton, FL | Public Health & General Preventive Medicine | $13,200.00 |
| David Dodick | New York, NY | Neurology (Psychiatry & Neurology) | $11,057.38 |
| Larry Charleston | East Lansing, MI | Neurology (Psychiatry & Neurology) | $10,600.00 |
| Phillip Gorelick | Chicago, IL | Vascular Neurology | $8,125.00 |
| Barry Davis | Houston, TX | Public Health & General Preventive Medicine | $4,550.00 |
| Timothy Smith | Saint Peters, MO | Internal Medicine | $3,850.00 |
| Andrew Blumenfeld | Carlsbad, CA | Neurology (Psychiatry & Neurology) | $3,757.36 |
| David Kudrow | Santa Monica, CA | Neurology (Psychiatry & Neurology) | $2,467.81 |
| Sarah Wood | Delray Beach, FL | Pediatrics | $2,100.00 |
Prescribed Aimovig?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.